Placebo Control

Results reporting requirements are pretty clear. Maybe critics should re-check their methods? Ben Goldacre has rather famously described t...

Even by the already-painfully-embarrassingly-low standards of clinical trial enrollment in general, patient enrollment in cancer clinical tr...

Are competing trials slowing yours down? Probably not. If they don't like your trial, EVERYTHING ELSE IN THE WORLD is competition fo...

'Competitive enrollment' is exactly that. This is a graph I tend to show frequently to my clients – it shows the relative enrollm...

ENACCT has released its final report on the outcomes from the National Cancer Clinical Trials Pilot Breakthrough Collaborative (NCCTBC) , a...

My recommended reading list -- highlights from the past week: Absolute required reading for anyone who designs protocols or is engaged in...

I have a lot of respect for Eric Topol, and am a huge fan of his ongoing work  to bring new mobile technology to benefit patients. The ...

A great article in Medscape reports on two unrelated articles on the FDA’s process for granting (and following up on) Accelerated Approvals...

Two intriguing articles on participation in clinical trials were published this week. Both happen to be about breast cancer, but both touch...